Abstract: The present invention provide a method of treating sexual dysfunction in a female, including the vasculogenic symptoms of delayed vaginal engorgement, diminished vaginal lubrication, pain or discomfort with intercourse (dyspareunia), diminished vaginal sensation, diminished vaginal orgasm, diminished clitoral sensation or diminished clitoral orgasm, or of combating vaginal pain by stimulating peripheral pelvic nerve release of nitric oxide (NO). The method comprises administering to a female in need of such treatment a therapeutically effective amount of a compound which acts on a mid-brain pathway to increase blood flow to the ilio-hypogastric-pudendal artery bed and stimulate the release of nitric oxide (NO) from peripheral NANC nerve cells. The preferred compound for the method of this invention is apomorphine or one of its pharmaceutically acceptable salts, esters, or pro-drugs.
Abstract: A method for detecting a prokaryotic organism while in the presence of or associated with a eukaryotic organism which comprises selectively hybridizing ribosomal RNA (rRNA) sequences of the prokaryotic organism with a detectably labelled prokaryotic rRNA information-containing hybridization probe; and detecting the label on the probe.
Abstract: The invention pertains to a single polypeptide chain binding molecule which has binding specificity and affinity substantially similar to the binding specificity and affinity of the light and heavy chain aggregate variable region of an antibody, to genetic sequences coding therefor, and to recombinant DNA methods of producing such molecule and uses for such molecule.
Type:
Grant
Filed:
April 25, 1990
Date of Patent:
November 9, 1993
Assignee:
Enzon, Inc.
Inventors:
Robert C. Ladner, Robert E. Bird, Karl Hardman
Abstract: A modified polypeptide material comprising an insoluble polypeptide carrier and synthetic polymer, the synthetic polymer made from (a) a polymerizable compound which has a chemical group capable of covalent coupling to the insoluble polypeptide carrier and (b) one or more polymerizable compounds containing an ionizable chemical group, a chemical group capable of transformation to an ionizable chemical group, a group capable of causing the covalent coupling of the synthetic polymer to an affinity ligand or a biologically active molecule, or a hydrophobic chemical group. The synthetic polymer is covalently bonded to the insoluble polypeptide carrier.
Abstract: A modified polysaccharide material which comprises: (1) polysaccharide covalently bonded to a synthetic polymer; (2) the synthetic polymer being made from (a) a polymerizable compound which is capable of being covalently coupled directly or indirectly to said polysaccharide, and (b) one or more polymerizable compounds containing (i) an ionizable chemcial group, (ii) a chemical group capable of transformation to an ionizable chemical group, (iii) a chemical group capable of causing the covalent coupling of the compound (b) to an affinity ligand or a biologically active molecule or (iv) a hydrophobic compound.